# MELT-MM: HCP commentary report

> 54 verified statements (15 from clinicians verified by NPI or staff page) from 14 commentary sources · 6 findings · updated Nov 1, 2026

## Report

- Trial: Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients
- NCT ID: NCT06645678
- Registry: https://clinicaltrials.gov/study/NCT06645678
- Sponsor: YOUNGIL KOH
- Phase: Phase 1/Phase 2
- Status: Recruiting
- Drugs tested: mezigdomide plus elranatamab plus dexamethasone
- Indication: relapsed/refractory multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-01
- Last checked: 2026-11-01
- Release hash: 8f281785edd017e4e4074854a5956b172b0360d0fdd3dea8fa1319761f3fac4d

## Counts

- HCP commentary sources screened: 25
- Sources cited by verified statements: 15
- Verified statements: 54
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 15
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 10
- Voices cited: 10
- Cited voices identity-verified: 7

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on MELT-MM in the sources reviewed for this edition leads to one open question: How much durable benefit does adding mezigdomide provide, for whom, and at what safety and delivery burden? Its leading findings: (1) the response signal is “striking,” but its durability and generalizability remain open. (2) manageable CRS is not a judgment that the whole combination is low burden. (3) deep MRD responses prompt a higher benchmark—not a cure or treatment-free conclusion. 3 more findings follow. 25 sources screened, 15 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

How much durable benefit does adding mezigdomide provide, for whom, and at what safety and delivery burden?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The response signal is “striking,” but its durability and generalizability remain open
- F2. Manageable CRS is not a judgment that the whole combination is low burden
- F3. Deep MRD responses prompt a higher benchmark—not a cure or treatment-free conclusion
- F4. T-cell reconditioning is the rationale; extending durability without switching remains a question
- F5. Alternative CELMoD partners are discussed through activity consistency and a possible safety advantage
- F6. Practice impact depends on safe delivery, affordability and research access

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 15 | 9 | 6 | 5 | recorded | 3 |
| F2 | 8 | 8 | 7 | 5 | recorded | 4 |
| F3 | 6 | 6 | 3 | 2 | recorded | 4 |
| F4 | 23 | 13 | 8 | 5 | none recorded | 4 |
| F5 | 4 | 3 | 3 | 2 | none recorded | 4 |
| F6 | 5 | 4 | 3 | 2 | none recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 1 | 0 | 1 | 7 | 16 | 4 | 3 posts and articles, 3 podcasts and video | yes |
| F2 | 6 | 0 | 0 | 1 | 1 | 8 | 1 | 4 posts and articles, 3 podcasts and video | yes |
| F3 | 4 | 0 | 0 | 0 | 2 | 8 | 1 | 2 posts and articles, 1 podcast or video | yes |
| F4 | 13 | 1 | 0 | 2 | 7 | 24 | 1 | 3 posts and articles, 5 podcasts and video | yes |
| F5 | 0 | 0 | 0 | 4 | 0 | 5 | 0 | 1 post or article, 2 podcasts and video | yes |
| F6 | 3 | 2 | 0 | 0 | 0 | 5 | 0 | 3 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Overall response rate (ORR): F1 (8 shared claims), F2 (1 shared claims), F3 (2 shared claims)
- Secondary endpoints: F1 (8 shared claims), F2 (2 shared claims), F3 (5 shared claims), F4 (2 shared claims), F5 (1 shared claims)
- Population and setting: F1 (7 shared claims), F2 (1 shared claims), F3 (4 shared claims), F4 (1 shared claims)
- The comparison: F1 (1 shared claims), F2 (1 shared claims), F4 (5 shared claims), F5 (4 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (8 shared claims), F4 (2 shared claims), F5 (1 shared claims), F6 (2 shared claims)
- Design and conduct: F1 (8 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (2 shared claims), F6 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 54 | Paid |
| Trial aspects mapped | 9 | Free |
| Sources with links | 15 | Counts free |
| Speaker attribution for cited voices | 10 | Paid |

## Trial aspects

9 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall response rate (ORR) | discussed | 9 | 6 |
| Secondary endpoints | discussed | 11 | 7 |
| Population and setting | discussed | 9 | 5 |
| The comparison | discussed | 8 | 7 |
| Safety and tolerability | discussed | 10 | 9 |
| Design and conduct | discussed | 12 | 8 |
| T-cell fitness, resistance and conditional sequencing hypotheses | discussed | 20 | 6 |
| Higher response benchmarks, de-escalation and cure-oriented interpretation | discussed | 5 | 3 |
| Indian practice impact, delivery burden and patient research access | discussed | 5 | 3 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 17 | 7 |
| YouTube | 5 | 5 |
| LinkedIn posts | 1 | 1 |
| Podcasts | 1 | 1 |
| Bluesky threads | 1 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2025-12-15 to 2026-10-25
- Cited window: 2025-12-15 to 2026-10-25
- Retrieved: 2026-11-01

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients
- Registry: NCT06645678 (https://clinicaltrials.gov/study/NCT06645678)
- Study IDs: H-2410-028-1576
- Sponsor: YOUNGIL KOH
- Design: Phase 1/Phase 2 · interventional, na, single group, phase1, phase2
- Status: Recruiting
- Enrollment: 75 (estimated)
- Start: 2024-11-26 (actual)
- Primary completion: 2026-10-01 (estimated)
- Primary endpoint: Overall response rate (ORR) (From C1D1 to confirmed PD, lost to follow-up, or death (whichever occurs first), assessed up to 24 months)
- Intervention: Elranatamab (drug)
- Intervention: Mezigdomide (drug)
- Intervention: Dexamethasone (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The report describes the sources reviewed for this edition, not the prevalence of views among HCPs. Reposts and overlapping media accounts are not independent clinician endorsements.
- Some potentially relevant passages were not fully assessed for additional views. Discussions using unnamed references or different terminology may also be missing, so coverage is not exhaustive.
- No standalone protocol, exact-trial results publication or exact mezigdomide label was available in the sources reviewed. Registry information describes planned methods and cannot verify the reported clinical outcomes.
- Small cohorts, evaluability exclusions and different follow-up cutoffs prevent pooling of the response and safety accounts or inference of changing efficacy over time.
- Some spoken passages remain unidentified despite names in publisher descriptions. An unclear response-category transcription and an incompletely transcribed marker have not been resolved by inference.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The same-combination safety post by a speaker does not name MELT-MM. It informs the clinical safety question but is not treated as a separately confirmed result of this trial.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-11-01: current edition

Last checked for new commentary 2026-11-01. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (54 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (7 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/melt-mm-nct06645678
- Agents: POST https://www.erudio.com/api/orders with {"report": "melt-mm-nct06645678", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=melt-mm-06645678

## Cite

Erudio Health. MELT-MM (NCT06645678): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/melt-mm-nct06645678

## Machine access

- JSON: https://www.erudio.com/reports/melt-mm-nct06645678.json
- Markdown: https://www.erudio.com/reports/melt-mm-nct06645678.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "melt-mm-06645678"}`